Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 7083016, 16 pages
https://doi.org/10.1155/2017/7083016
Research Article

Cardioprotection against Heart Failure by Shenfu Injection via TGF-β/Smads Signaling Pathway

Jingyu Ni,1,2,3,4 Yang Shi,2,3,4 Lan Li,2,3,4 Jingrui Chen,2,3,4 Lingyan Li,2,3,4 Min Li,2,3,4 Jinqiang Zhu,2,3,4 Yan Zhu,2,3,4 and Guanwei Fan1,2,3,4

1First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
2Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin 300193, China
3Ministry of Education, Key Laboratory of Formula of Traditional Chinese Medicine, Tianjin 300193, China
4Tianjin Key Laboratory of Traditional Chinese Medicine Pharmacology, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China

Correspondence should be addressed to Guanwei Fan; moc.liamtoh@5001wgf

Received 2 March 2017; Accepted 2 May 2017; Published 15 June 2017

Academic Editor: Giuseppe Caminiti

Copyright © 2017 Jingyu Ni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. J. V. McMurray, S. Adamopoulos, S. D. Anker et al., “ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the heart Failure Association (HFA) of the esc,” European Heart Journal, vol. 33, no. 14, pp. 1787–1847, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. W. C. Yancy, M. Jessup, B. Bozkurt et al., “2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation, vol. 128, pp. e240–e327, 2013. View at Publisher · View at Google Scholar
  3. D. Gu, G. Huang, J. He et al., “Investigation of prevalence and distributing feature of chronic heart failure in Chinese adult population,” Chinese Journal Cardiology, vol. 31, no. 1, pp. 3–6, 2003. View at Google Scholar
  4. M. J. Radford, J. M. O. Arnold, S. J. Bennett et al., “ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards),” Circulation, vol. 112, no. 12, pp. 1888–1916, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. A. S. Go, D. Mozaffarian, V. L. Roger et al., “Heart disease and stroke statistics—2014 update: a report from the American Heart Association,” Circulation, vol. 129, pp. e28–e292, 2014. View at Google Scholar
  6. S. W. M. Van Den Borne, J. Diez, W. M. Blankesteijn, J. Verjans, L. Hofstra, and J. Narula, “Myocardial remodeling after infarction: the role of myofibroblasts,” Nature Reviews Cardiology, vol. 7, no. 1, pp. 30–37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. G. Sutton and N. Sharpe, “Left ventricular remodeling after myocardial infarction: pathophysiology and therapy,” Circulation, vol. 101, no. 25, pp. 2981–2988, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Distefano and P. Sciacca, “Molecular pathogenesis of myocardial remodeling and new potential therapeutic targets in chronic heart failure,” Italian Journal of Pediatrics, vol. 38, no. 1, article 41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Oury, L. Servais, N. Bouznad, A. Hego, A. Nchimi, and P. Lancellotti, “MicroRNAs in valvular heart diseases: potential role as markers and actors of valvular and cardiac remodeling,” International Journal of Molecular Sciences, vol. 17, no. 7, article 1120, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Zhong, H. Wang, S. Yang et al., “Targeting Smad4 links microRNA-146a to the TGF-β pathway during retinoid acid induction in acute promyelocytic leukemia cell line,” International Journal of Hematology, vol. 92, no. 1, pp. 129–135, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Vaidya and V. P. Kale, “TGF-β signaling and its role in the regulation of hematopoietic stem cells,” Systems and Synthetic Biology, vol. 9, no. 1, pp. 1–10, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. M. Pinto, S.-J. Pinto-Sietsma, T. Philipp et al., “Reduction in left ventricular messenger RNA for transforming growth factor β1 attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2) 27 rat,” Hypertension, vol. 36, no. 5, pp. 747–754, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Miyazawa, M. Shinozaki, T. Hara, T. Furuya, and K. Miyazono, “Two major Smad pathways in TGF-β superfamily signalling,” Genes to Cells, vol. 7, no. 12, pp. 1191–1204, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. X.-M. Meng, P. M.-K. Tang, J. Li, and H. Y. Lan, “TGF-β/Smad signaling in renal fibrosis,” Frontiers in Physiology, vol. 6, article 82, 2015. View at Publisher · View at Google Scholar
  15. F. Verrecchia and A. Mauviel, “Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation,” Journal of Investigative Dermatology, vol. 118, no. 2, pp. 211–215, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. H. Li, B. Yu, Z. Z. Duan et al., “The coronary dilation effect of Shen Fu injection was mediated through NO,” PLoS ONE, vol. 9, no. 3, Article ID e92415, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. Y.-L. Wang, C.-Y. Wang, B.-J. Zhang, and Z.-Z. Zhang, “Shenfu injection suppresses apoptosis by regulation of Bcl-2 and caspase-3 during hypoxia/reoxygenation in neonatal rat cardiomyocytes in vitro,” Molecular Biology Reports, vol. 36, no. 2, pp. 365–370, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. X.-Y. Luo, F.-R. Zhang, and R.-M. He, “Efficacy of shenfu injection as adjuvant therapy in treating patients of ischemic cardiomyopathy with heart insufficiency,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 29, no. 8, pp. 685–687, 2009. View at Google Scholar · View at Scopus
  19. C.-D. Zheng and S. Min, “Cardioprotection of Shenfu Injection against myocardial ischemia/reperfusion injury in open heart surgery,” Chinese Journal of Integrative Medicine, vol. 14, no. 1, pp. 10–16, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. W.-T. Song, F.-F. Cheng, L. Xu, C.-R. Lin, and J.-X. Liu, “Chinese medicine shenfu injection for heart failure: a systematic review and meta-analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 713149, 25 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Maki, Y. Nasa, K. Tanonaka, M. Takahashi, and S. Takeo, “Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation,” Journal of Pharmacology and Experimental Therapeutics, vol. 305, no. 1, pp. 97–105, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. B. L. Zhang, Y. Su, X. M. Gao, Z. L. Dong, Z. P. Xu, and X. H. Wang, “Clinical and experimental research of compound huangqi danshen granule on treating angina pectoris,” Tianjin Journal of Traditional Chinese Medicine, vol. 4, no. 19, pp. 12–15, 2002. View at Google Scholar
  23. D. Ai, W. Pang, N. Li et al., “Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy,” Proceedings of the National Academy of Sciences, vol. 106, no. 2, pp. 564–569, 2009. View at Publisher · View at Google Scholar
  24. Y. C. Li, Y. Y. Liu, B. H. Hu et al., “Attenuating effect of post-treatment with QiShenYiQi Pills on myocardial fibrosis in rat cardiac hypertrophy,” Clinical Hemorheology & Microcirculation, vol. 51, no. 3, pp. 177–191, 2012. View at Google Scholar
  25. S.-Q. Lin, X.-H. Wei, P. Huang et al., “Qi Shen Yi Qi Pills prevents cardiac ischemia-reperfusion injury via energy modulation,” International Journal of Cardiology, vol. 168, no. 2, pp. 967–974, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. X. Yan, J. Xue, H. Wu et al., “Ginsenoside-Rb1 protects hypoxic- and ischemic-damaged cardiomyocytes by regulating expression of miRNAs,” Evidence-based Complementary and Alternative Medicine, vol. 2015, Article ID 171306, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Zhu, L. Kang, Q. Ye et al., “Effects of Shenfu injection and its main components on the contraction of isolated rat thoracic aortic rings,” PloS one, vol. 8, no. 10, Article ID e78026, 2013. View at Google Scholar · View at Scopus
  28. K. S. C. Cheung, N. Sposito, P. S. Stumpf, D. I. Wilson, T. Sanchez-Elsner, and R. O. C. Oreffo, “MicroRNA-146a regulates human foetal femur derived skeletal stem cell differentiation by down-regulating SMAD2 and SMAD3,” PLoS ONE, vol. 9, no. 6, Article ID e98063, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. He, C. Huang, X. Sun, X.-R. Long, X.-W. Lv, and J. Li, “MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4,” Cellular Signalling, vol. 24, no. 10, pp. 1923–1930, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Costantino, F. Paneni, T. F. Lüscher, and F. Cosentino, “MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart,” European Heart Journal, vol. 37, no. 6, pp. 572–576, 2016. View at Publisher · View at Google Scholar
  31. M. Bujak and N. G. Frangogiannis, “The role of TGF-β signaling in myocardial infarction and cardiac remodeling,” Cardiovascular Research, vol. 74, no. 2, pp. 184–195, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. L. J. Ellmers, N. J. A. Scott, S. Medicherla et al., “Transforming growth factor-β blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction,” Endocrinology, vol. 149, no. 11, pp. 5828–5834, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. M. A. Pfeffer and E. Braunwald, “Ventricular remodeling after myocardial infarction: experimental observations and clinical implications,” Circulation, vol. 81, no. 4, pp. 1161–1172, 1990. View at Publisher · View at Google Scholar · View at Scopus
  34. M. E. Liquori, R. H. Christenson, P. O. Collinson, and C. R. deFilippi, “Cardiac biomarkers in heart failure,” Clinical Biochemistry, vol. 47, no. 6, pp. 327–337, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. X. He, X. Gao, L. Peng et al., “Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7,” Circulation Research, vol. 108, no. 2, pp. 164–175, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Oishi, R. Ozono, M. Yoshizumi, M. Akishita, M. Horiuchi, and T. Oshima, “AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling,” Life Sciences, vol. 80, no. 1, pp. 82–88, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Harada, T. Sugaya, K. Murakami, Y. Yazaki, and I. Komuro, “Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction,” Circulation, vol. 100, no. 20, pp. 2093–2099, 1999. View at Publisher · View at Google Scholar · View at Scopus